<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Following <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, i.v. infusion of <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> increases <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> and mortality </plain></SENT>
<SENT sid="1" pm="."><plain>Angiotensin type 1 receptor blockage should therefore improve <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Left middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (120 min) followed by reperfusion was performed with the thread method under <z:chebi fb="2" ids="5615">halothane</z:chebi> anesthesia in Sprague-Dawley rats </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="48416">Olmesartan</z:chebi> (angiotensin type 1 receptor blocker; 0.01 or 0.1mumol/kg/h) was infused i.p. for 7 days following middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> followed by reperfusion </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0001297'>Stroke</z:hpo> index score, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, specific gravity, and brain <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> and matrix metalloproteinases were quantified in the ischemic and non-ischemic hemispheres </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="48416">Olmesartan</z:chebi> treatment improved <z:hpo ids='HP_0001297'>stroke</z:hpo> index score, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, and <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> in our <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> model </plain></SENT>
<SENT sid="6" pm="."><plain>In particular, <z:hpo ids='HP_0001297'>stroke</z:hpo> index score, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, and <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> were reduced even with a low dose of <z:chebi fb="0" ids="48416">olmesartan</z:chebi> that did not decrease blood pressure </plain></SENT>
<SENT sid="7" pm="."><plain>Paralleling these effects on <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, <z:chebi fb="0" ids="48416">olmesartan</z:chebi> treatment also reduced the reactive upregulation in brain <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi>, matrix metalloproteinase-2, matrix metalloproteinase-9, and membrane type 1-matrix metalloproteinase in the ischemic area </plain></SENT>
<SENT sid="8" pm="."><plain>Angiotensin type 1 receptor stimulation may be one of the important factors that cause <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> following <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, and that its inhibition may be of therapeutic advantage in <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
</text></document>